key: cord-1051724-ekwquby2
authors: HALL, MICHAEL E.; VADUGANATHAN, MUTHIAH; KHAN, MUHAMMAD SHAHZEB; PAPADIMITRIOU, LAMPROS; LONG, ROBERT C.; HERNANDEZ, GABRIEL A.; MOORE, CHARLES K.; LENNEP, BRANDON W.; MCMULLAN, MICHAEL R.; BUTLER, JAVED
title: Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic
date: 2020-05-13
journal: J Card Fail
DOI: 10.1016/j.cardfail.2020.05.005
sha: ef5f81ea3c369b1fa1c5aaed64c060ce2618bf2b
doc_id: 1051724
cord_uid: ekwquby2

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has increased burden on healthcare systems with subsequent reductions in non-emergent hospitalizations and procedures. While there are widespread reports of intentional reductions in elective hospitalizations, trends in urgent or emergent hospitalizations including heart failure (HF) hospitalizations have not been adequately characterized. METHODS: We evaluated trends of HF hospitalizations before and during the COVID-19 pandemic at the University of Mississippi Medical Center using electronic health records and discharge database. We also compared HF hospitalization trends during the same time frame in 2019 to account for seasonal variation in HF presentations. RESULTS: Prior to the COVID-19 pandemic in our medical center, a mean of 30 patients per week were admitted with a principal diagnosis of HF. After the first case of COVID-19 was diagnosed in Mississippi, there was a sharp 50% decline in the number of HF hospitalizations that declined even further after a “state of emergency” was declared in Mississippi. CONCLUSIONS: Based on observations from a large academic medical center, there has been a significant reduction in the number of patients hospitalized for HF during the COVID-19 pandemic. Further investigation of these trends is warranted to determine the effects of the COVID-19 pandemic on long-term HF outcomes.

The coronavirus disease 2019 pandemic has created tremendous strain on healthcare systems worldwide, both in terms of patient care in several geographies and more globally in planning for its anticipated surge. In preparation for increased numbers of patients with severe respiratory compromise, many hospitals have intentionally reduced non-emergent procedures and hospitalizations to preserve hospital capacity and personal protective equipment. In some places, state directives mandate this. These plans and directives should not influence admissions from the emergency department for acute cardiovascular conditions, including heart failure (HF).

We examined trends in HF hospitalizations across a large, tertiary care academic medical center using the electronic health record system and hospital discharge database.

Hospitalizations with a principal diagnosis of HF (acute or acute on chronic based on ICD-10 codes) were included in this analysis. We examined weekly HF hospitalizations beginning in January 2020 prior to the first case of COVID-19 in the United States 1 through April 11. We also compared trends in HF hospitalizations from 2019 during the same time period to account for the potential for residual confounding based on seasonal trends in HF hospitalizations. All HF subtypes including HF with reduced ejection fraction (HFrEF), preserved ejection fraction (HFpEF) and mid-range ejection fraction (HFmrEF) subtypes were included in this analysis.

Weekly HF hospitalizations by year (2019 and 2020) are displayed in Figure 1 along with important events related to the pandemic. In the two weeks prior to the first diagnosed case of COVID-19 in Mississippi, HF cases averaged 30 per week. After the first diagnosed case in Mississippi, mean HF hospitalizations declined by 50% to 15 per week. HF hospitalizations continued to decline to lower levels after a "state of emergency" was declared and even further after the statewide "shelter in place" was mandated, with fewer HF hospitalizations in the last two weeks of this analysis. Although we observed week-toweek variability in HF hospitalizations in 2019, we did not observe significant and progressive declines similar to those noted during the current COVID-19 pandemic. Before the first case of COVID-19 was identified in the state of Mississippi, 68.1% of HF cases were HFrEF subtype, 22.4% HFpEF and 9.5% HFmrEF. We observed a very similar distribution of HF subtypes after March 12 including 65.9% HFrEF, 26.8% HFpEF and 7.3% HFmrEF. Our observations from a large tertiary care academic medical center indicate that there was a marked decline in HF hospitalizations during the COVID-19 pandemic. With rare exceptions, most HF hospitalizations are non-elective and represent worsening congestion that can have significant impact on patient outcomes if not treated or delayed.

Theoretically, these hospitalizations are not expected to be affected by hospital or health authority policies. This is particularly true for large, tertiary care referral centers that offer advanced therapies. On the other hand, such centers are likely to also take care of many of the sickest COVID-19 patients. Therefore, it is possible that patients with non-COVID-19 related illnesses may be concerned about the potential for their own risk for nosocomial infection when in the hospital getting treatment for other urgent medical conditions such as HF. Importantly, there was no announcement at either the health system or state health department levels to divert patients with certain medical conditions to specific hospitals.

To this point, there were similar numbers of transfers for HF to our institution before and during the COVID-19 pandemic (mean 4.0 ± 2.8 vs 3.0 ± 1.8 transfers per week, respectively).

A major concern is that these declines in HF hospitalizations may be due to patient fears of medical facilities, and the "weathering the storm" mentality by patients until the COVID-19 pandemic abates. Further urgent attention to understand and mitigate these patterns, including plans for alternative monitoring and therapeutic approaches to improve HF treatment are warranted during these unprecedented times.

Pillai SK; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States

JB declares that he serves as a consultant for Abbott

The authors would like to thank Mrs. Melissa Stampley for her assistance in collection of the HF hospitalization data.

MH is funded by grants from the National Institutes of Health grants 1K08DK099415 (NIDDK) and 5U54GM115428 (NIGMS).